Neonc Technologies Holdings, Inc. (NTHI) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Calabasas, CA, United States. The current CEO is Amir Farrokh Heshmatpour.
NTHI has IPO date of 2025-03-26, 8 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $103.17M.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
